New Study Shows DeepHealth AI Could Help Avoid Nearly One in Five Prostate Biopsies
Key Highlights
- ➤AI-assisted approach could have avoided 149 biopsies, or 18.9% of procedures
- ➤Approach maintained 98.4% sensitivity for clinically significant prostate cancer
- ➤Study analyzed 787 men across Germany, the Netherlands and United States
- ➤DeepHealth Prostate MR Solution integrates lesion detection, risk classification and PSA density calculation
- ➤DeepHealth is RadNet’s wholly owned AI and digital health subsidiary (RDNT)
Expert Statements
Niccolò Stefani, M.D., Business and Product Leader, Clinical AI, DeepHealth
“These findings show how AI applications within our Prostate MR Solution can support clinicians at one of the most consequential decision points in prostate care”
Niccolò Stefani, M.D., Business and Product Leader, Clinical AI, DeepHealth
“Our aim is to help care teams make more informed decisions about the next step for each patient.”
Niccolò Stefani, M.D., Business and Product Leader, Clinical AI, DeepHealth
“As part of our broader clinical AI portfolio, our Prostate MR Solution is designed to bring additional insight into the clinical workflow, with clinical judgment at the center.”
Francesco Giganti, M.D., Professor of Radiology at University College London and senior author of the study
“When an MRI finding is uncertain, deciding whether to recommend a biopsy can be difficult”
Francesco Giganti, M.D., Professor of Radiology at University College London and senior author of the study
“Our findings suggest that AI could provide another piece of evidence to help clinicians make that decision.”
Francesco Giganti, M.D., Professor of Radiology at University College London and senior author of the study
“The opportunity is to use DeepHealth’s Prostate MR Solution to better identify which men may benefit from a biopsy, with the final medical decision remaining with the clinical team.”
SOMERVILLE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced new findings published in European Radiology supporting that AI applications within DeepHealth’s Prostate MR Solution(1) could help clinicians decide more confidently which men may need a prostate biopsy, particularly when MRI findings are uncertain.(2)
Prostate cancer is the second most commonly diagnosed cancer among men worldwide, with an estimated 1.55 million new cases in 2024.(3) MRI helps clinicians assess whether prostate cancer may be present, but some findings remain uncertain.(4) A biopsy involves collecting small tissue samples to check for cancer and, if found, assess its grade. While biopsies are essential for diagnosis, they are invasive and can sometimes find no cancer or only low-grade disease that may not need treatment.(4,)(5) Reducing unnecessary biopsies can spare some men related risks and help focus care on those most likely to benefit.
Get started
Create a free account to read the full story.